Search Results - "Hellmis, E."

Abiraterone acetate plus prednisone and LHRH therapy versus abiraterone acetate plus prednisone while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634) by Ohlmann, C., Roger, Z., Rüssel, C., Hellmis, E., Suttmann, H., Janssen, M., Hübner, A., Dahm, J., Gleißner, J., Scheffler, M., Feyerabend, S., Telle, J., Klier, J.

Get full text

Analyse des Einflusses der zunehmenden Feminisierung im Gesundheitswesen auf die Urologie by Himmler, M, Schultz-Lampel, D, Hellmis, E, Kowalewski, K. F, Michel, M. S, Weinberger, S

“…ZusammenfassungHintergrund und FragestellungZiel dieser wissenschaftlichen Arbeit war es, Genderaspekte und Trends in Klinik, Forschung und Niederlassung in…”
Get full text

1890P Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH) by Darr, C., Ivanyi, P., Wirth, M., Zschäbitz, S., Schostak, M., Mueller, L., Steiner, T., Welslau, M.K., Schuett, P., Lorch, A., Rafiyan, M-R., Hellmis, E., Meiler, J., Kretz, T., Loidl, W.C., Floercken, A., Stöhr, C.G., Eckstein, M., Hartmann, A., Grünwald, V.

Get full text

679P Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH) by Darr, C., Zschäbitz, S., Ivanyi, P., Wirth, M., Staib, P., Schostak, M., Müller, L., Metz, M., Bergmann, L., Steiner, T., Lorch, A., Schütt, P., Rafiyan, M-R., Hellmis, E., Hinke, A., Mänz, M., Meiler, J., Kretz, T., Flörcken, A., Grünwald, V.

Get full text

810PAbiraterone acetate plus prednisone and LHRH therapy versus abiraterone acetate plus prednisone while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634) by Ohlmann, C, Roger, Z, Rüssel, C, Hellmis, E, Suttmann, H, Janssen, M, Hübner, A, Dahm, J, Gleißner, J, Scheffler, M, Feyerabend, S, Telle, J, Klier, J

Get full text

959P - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH) by Grünwald, V., Grüllich, C., Ivanyi, P., Wirth, M., Staib, P., Schostak, M., Dargatz, P., Müller, L., Metz, M., Bergmann, L., Welslau, M.K., Schütt, P., Rafiyan, M.-R., Hellmis, E., Hinke, A., Meiler, J., Kretz, T., Loidl, W.C., Flörcken, A., Steiner, T.

“…Tyrosine kinase inhibitors (TKI) and nivolumab (NIVO) are key components of systemic therapies in metastatic renal cell carcinoma (mRCC). We tested if TKI…”
Get full text

A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH) by Grünwald, V., Grüllich, C., Ivanyi, P., Wirth, M., Staib, P., Schostak, M., Dargatz, P., Müller, L., Metz, M., Bergmann, L., Welslau, M.K., Schütt, P., Rafiyan, M.-R., Hellmis, E., Hinke, A., Meiler, J., Kretz, T., Loidl, W.C., Flörcken, A., Steiner, T.

Get full text

P128 ArtemisR: Final analysis of a European real-world retrospective study of mHSPC patients treated with apalutamide by Kramer, G., Bennamoun, M., Dourthe, L.M., Encarnacion, J.A., Hegele, A., Hellmis, E., Latorzeff, I., Leicht, W., Onate-Celdran, J., Rosino- Sánchez, A., Lencart, J., Lukac, M., Pissart, G., Schioppa, C.A., Van Sanden, S., Boegemann, M.

Get full text

959PA phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH) by Grünwald, V, Grüllich, C, Ivanyi, P, Wirth, M, Staib, P, Schostak, M, Dargatz, P, Müller, L, Metz, M, Bergmann, L, Welslau, M K, Schütt, P, Rafiyan, M-R, Hellmis, E, Hinke, A, Meiler, J, Kretz, T, Loidl, W C, Flörcken, A, Steiner, T

“…Abstract Background Tyrosine kinase inhibitors (TKI) and nivolumab (NIVO) are key components of systemic therapies in metastatic renal cell carcinoma (mRCC)…”
Get full text

Sparing androgen-deprivation therapy upon treatment with abiraterone in patients with chemotherapy-naive castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634) by Ohlmann, C.H., Zilmann, R., Rüssel, C., Hellmis, E., Suttmann, H., Janssen, M., Marin, J., Hübner, A., Dahm, J., Gleißner, J., Scheffler, M., Feyerabend, S., Telle, J., Jäschke, M., Klier, J.

Get full text

1035 - Sparing androgen-deprivation therapy upon treatment with abiraterone in patients with chemotherapy-naive castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634) by Ohlmann, C.H., Zilmann, R., Rüssel, C., Hellmis, E., Suttmann, H., Janssen, M., Marin, J., Hübner, A., Dahm, J., Gleißner, J., Scheffler, M., Feyerabend, S., Telle, J., Jäschke, M., Klier, J.

Get full text

PROPIVERINE COMPARED TO OXYBUTYNIN IN CHILDREN WITH IDIOPATHIC DETRUSOR OVERACTIVITY – ARE EFFICACY AND TOLERABILITY COMPARABLE? by Alloussi, S., Muertz, G., Braun, R., Gerhardt, U., Heinrich, M., Hellmis, E., Horn, W., Hossfeld, A., Marschall-Kehrel, A.D., Niklas, K., Raabe, M., Rössler, T., Schultz-Lampel, D., Seibt, B., Siemer, S., Walter, H., Wiedeking, B., Willer, B., Bock, P., Hanisch, J.

Get full text